Wall Street Zen Upgrades Telomir Pharmaceuticals (NASDAQ:TELO) to Hold

Telomir Pharmaceuticals (NASDAQ:TELO) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other research analysts also recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, January 22nd. Rodman & Renshaw started coverage on shares of Telomir Pharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Telomir Pharmaceuticals Stock Performance

Shares of NASDAQ TELO opened at $1.14 on Friday. The stock has a market cap of $39.19 million, a PE ratio of -3.08 and a beta of -0.49. Telomir Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $5.40. The stock has a fifty day moving average of $1.30 and a 200-day moving average of $1.40.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TELO. OneDigital Investment Advisors LLC lifted its holdings in shares of Telomir Pharmaceuticals by 64.3% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 23,000 shares of the company’s stock worth $32,000 after acquiring an additional 9,000 shares during the last quarter. Bank of America Corp DE increased its stake in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after acquiring an additional 10,880 shares during the last quarter. Praetorian Wealth Management Inc. purchased a new stake in Telomir Pharmaceuticals during the third quarter valued at about $28,000. Qube Research & Technologies Ltd bought a new stake in Telomir Pharmaceuticals during the second quarter worth about $33,000. Finally, Geode Capital Management LLC lifted its stake in Telomir Pharmaceuticals by 14.0% during the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock worth $297,000 after purchasing an additional 27,519 shares during the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.